Prevention of Medication-related Osteonecrosis of the Jaw (MR-ONJ) after dentoalveolar surgery in cancer patients: one year experience.

Medication-related Osteonecrosis of the Jaw (MR-ONJ) is an adverse drugs reaction characterized by the worsening of quality of life in cancer patients, and for which one of the most frequent risk factor recognized is tooth extraction.  This report aims to describe our one-year experience about the prevention of MR-ONJ in cancer patients receiving antiresorptive-antiangiogenic drugs, with or without Bisphosphonates, referred to the Department of Surgical Sciences, Paediatrics and Gynaecology (University of Verona). The protocol described by the Italian Society of Oral and Maxillofacial Surgery (SICMF) and the Italian Society of Oral Pathology and Medicine (SIPMO) was strictly followed in all surgical procedures, including the defined medical prophylaxis. Once assessed inclusion and exclusion criteria, a retrospective analysis was carried out in a total of 15 patients, followed up during 2019. None of our patients developed MR-ONJ.